about
Unlocking proteomic heterogeneity in complex diseases through visual analyticsHow drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionReproducible Research Practices and Transparency across the Biomedical LiteratureIs There a Space-Based Technology Solution to Problems with Preclinical Drug Toxicity Testing?Predictive biomarkers in precision medicine and drug development against lung cancerAdvancing Biological Understanding and Therapeutics Discovery with Small-Molecule ProbesMurine models of inflammatory bowel disease (IBD): challenges of modeling human diseaseDREADDs: novel tools for drug discovery and developmentLost in translation: animal models and clinical trials in cancer treatmentRisk in vaccine research and development quantifiedPhenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanismsLook back in anger - what clinical studies tell us about preclinical workPortfolio Decisions in Early DevelopmentEarly repositioning through compound set enrichment analysis: a knowledge-recycling strategy.A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells.Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesisCan animal data translate to innovations necessary for a new era of patient-centred and individualised healthcare? Bias in preclinical animal researchIdentification of in vitro and in vivo disconnects using transcriptomic dataPotential applications and human biosafety of nanomaterials used in nanomedicineDetecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensorFrom computational modelling of the intrinsic apoptosis pathway to a systems-based analysis of chemotherapy resistance: achievements, perspectives and challenges in systems medicine.Bringing together the academic drug discovery community.The future of molecular dynamics simulations in drug discovery.Data mining reveals a network of early-response genes as a consensus signature of drug-induced in vitro and in vivo toxicityPersonalizing health care: feasibility and future implications.Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory DiseasesThe future of the development of medicines in idiopathic pulmonary fibrosis.Phenotypic screens as a renewed approach for drug discovery.Large-scale prediction and testing of drug activity on side-effect targets.Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.The power of boolean implication networks.Drug repositioning for personalized medicine.Hallmarks of therapeutic management of the cystic fibrosis functional landscape.Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-Findings from a Qualitative Study.Emphasising the European Union's Commitment to Cancer Research: a helicopter view of the Seventh Framework Programme for Research and Technological Development.WITHDRAWN--a resource for withdrawn and discontinued drugsEvaluation of cholesterol reduction activity of methyl-β-cyclodextrin using differentiated human neurons and astrocytes.An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) projectBest Practice BioBanking of Human Heart TissueMechanistic biomarkers for clinical decision making in rheumatic diseases.
P2860
Q23921986-63657A43-721E-49CA-897E-0134B2E15381Q24273350-F35CF6D7-081F-461D-903E-6F8121B5CD70Q24288789-539AC0CA-6EEF-4F84-B87D-F63F598B511CQ26749381-60B5F40D-4594-4551-9384-E83D9EA4DCD6Q26824536-1E56800B-FA5C-428A-A670-B2C864C04D9EQ26829985-BF1491CE-1F56-45B4-A0A1-A9957B8F980DQ26863622-C0FAEC11-2BD2-4D83-A3BA-A00EFE73D136Q26995396-2A358755-FAB4-418F-9E90-B380B8D5E91BQ27000792-F5D793C7-C3F7-4567-8D68-8DF48272446EQ28488506-DC1DE0EF-3372-4DB9-8ED2-9E45F4598F5DQ28530398-618AD9F5-2106-4561-B6DB-78158FF97659Q28677000-CC2B6234-9A0E-4FAC-A4B2-3D51A59815B9Q29999056-CD038750-6993-4F1C-931F-BB441A677623Q30486820-9673A26A-A4F5-43F5-BC9C-55A26AD825A7Q30539598-53566A94-5E60-4DC6-9ED4-D19A9B4107ABQ30968128-278D2013-23F3-41D1-9101-C5B710DF0FD9Q30983045-9EE07809-80CF-47CA-A4B3-F6A6ACF3ED73Q30987816-823A7616-EC63-4F73-B5FC-6071BAF2133BQ32944368-87D63B13-696E-4FB1-B607-FB027DA0ADE6Q33647681-5552C4D0-F170-4760-B2E1-ADC6553F1111Q33720383-5AD224A4-5468-4360-AFC6-2C3540C93E4DQ33824937-68A4F541-8DDA-4076-BBAF-1F4CAD9674E5Q34241696-FFFE23D8-CF14-496D-BF9E-87C9DC3BCE20Q34384283-0518A27C-BFDB-4471-A072-E3142834D72CQ34938911-CD50E28D-7626-4560-8272-C289502E205FQ35738486-7061A597-F65B-4D5A-B2FC-354E8DB1F8CBQ35785682-5F1AB10F-B0AA-4565-8B09-8ABFD514573CQ35936197-886FE4B2-6918-4567-9E02-B05F31ACE422Q36059863-F4127938-1ABB-42AD-B5F4-1C49E7EC4D65Q36063631-149CF682-3339-414E-8FDC-E9E0F7864E4FQ36193716-6860D15A-0F29-4B26-BDFF-FC312434EBBDQ36245193-B7D5CEF1-73E1-45DB-A7B1-0790F8C1866EQ36279553-D867DA5D-31C3-4A62-BC11-4A6C033B676CQ36326130-BF01CCF9-C0A9-4DC2-AF45-5A89F4EA3219Q36349630-9E9FB7F3-43CB-4119-91A2-739A3820B2BAQ36434790-3E969CFE-F7CE-40D1-B462-53FFAA695317Q36488887-6DF4379C-35BB-4F99-8E0D-53B909766713Q36570348-D152544B-EBA8-49D2-890D-F9BC7705D5D3Q36688868-099691D0-2499-4732-88E6-957FF55C68EEQ36905584-34F9DE50-6432-4F0C-9652-AB8FB681D9E8
P2860
description
article
@en
im Februar 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2011
@uk
ലേഖനം
@ml
name
Phase III and submission failures: 2007–2010
@en
Phase III and submission failures: 2007–2010
@nl
type
label
Phase III and submission failures: 2007–2010
@en
Phase III and submission failures: 2007–2010
@nl
prefLabel
Phase III and submission failures: 2007–2010
@en
Phase III and submission failures: 2007–2010
@nl
P356
P1476
Phase III and submission failures: 2007–2010
@en
P2093
John Arrowsmith
P2888
P356
10.1038/NRD3375
P577
2011-02-01T00:00:00Z